The total number of shares in Caverion is 138,920,092 and the share capital is EUR 1,000,000. There have been no changes in the share capital. Caverion holds 1,873,825 treasury shares.
|
Year |
Event |
Number of shares |
|---|---|---|
|
2022 |
No changes. |
138,920,092 |
|
2021 |
No changes. |
138,920,092 |
|
2020 |
No changes. |
138,920,092 |
|
2019 |
No changes. |
138,920,092 |
|
2018 |
18 June 2018: Directed share issue of 9,524,000 new shares to institutional investors. |
138,920,092 |
|
|
19 February 2018: Issue of 3,800,000 new shares directed to the company itself without payment related to MSP 2018−2022 execution. |
|
|
2017 |
No changes. |
125,596,092 |
|
2016 |
No changes. |
125,596,092 |
|
2015 |
No changes. |
125,596,092 |
|
2014 |
No changes. |
125,596,092 |
|
2013 |
No changes as of the commencement of trading on 1 July 2013. |
125,596,092 |
Authorising Caverion's Board of Directors to decide on share issues
The Annual General Meeting of Caverion Corporation, held on 27 March 2023, authorised the Board of Directors to decide on share issues in accordance with the proposal by the Board of Directors. The number of shares to be issued under the authorization may not exceed 13,500,000 shares, which corresponds to approximately 9.7% of all the shares in the Company.
The Board of Directors decides on all the conditions of the issuance of shares. The authorisation concerns both the issuance of new shares as well as the transfer of treasury shares. The issuance of shares may be carried out in deviation from the shareholders’ pre-emptive rights (directed issue). The authorisation can be used, e.g. in order to develop the Company’s capital structure, to broaden the Company’s ownership base, to be used as payment in corporate acquisitions or when the Company acquires assets relating to its business and as part of the Company’s incentive programs.
The authorisation cancels the authorisation given by the Annual General Meeting on 28 March 2022 to decide on the issuance of shares. The authorization is valid until the end of the next Annual General Meeting, however no later than 30 June 2024.
Authorising Caverion's Board of Directors to decide on the repurchase and/or on the acceptance as pledge of own shares of the company
The Annual General Meeting of Caverion Corporation, held on 27 March 2023 authorised the Board of Directors to decide on the repurchase and/or on the acceptance as pledge of the Company’s own shares in accordance with the proposal by the Board of Directors. The number of own shares to be repurchased and/or accepted as pledge shall not exceed 13,500,000 shares, which corresponds to approximately 9.7% of all the shares in the Company. The Company may use only unrestricted equity to repurchase own shares on the basis of the authorisation.
Purchase of own shares may be made at a price formed in public trading on the date of the repurchase or otherwise at a price formed on the market. The Board of Directors resolves the manner in which own shares will be repurchased and/or accepted as pledge. Repurchase of own shares may be made using, inter alia, derivatives. The repurchase and/or acceptance as pledge of own shares may be made otherwise than in proportion to the share ownership of the shareholders (directed repurchase or acceptance as pledge).
The authorization cancels the authorisation given by the Annual General Meeting on 28 March 2022 to decide on the repurchase and/or acceptance as pledge of the Company’s own shares. The authorisation is valid until 27 September 2024.
As part of the implementation of the Matching Share Plan announced on 7 February 2018, the company has accepted as a pledge the shares acquired by those key employees who took a loan from the company. As a result, Caverion had 170,630 Caverion Corporation shares as a pledge at the end of the reporting period on 30 June 2023.